Lucid Diagnostics Inc. announced that it has entered into subscription agreements and exchange agreements with certain accredited investors, which agreements provided for the sale to the Series B Investors of 12,495 shares of the Company?s newly designated Series B Convertible Preferred Stock, par value $0.001 per share at a purchase price of $1,000 per share for the gross proceeds of $12,495,000; the exchange by the Series B Investors of 13,625 shares of the Company?s Series A Convertible Preferred Stock, par value $0.001 per share and 10,670 shares of the Company?s Series A-1 Convertible Preferred Stock, par value $0.001 per share held by them for 31,790 shares of Series B Preferred Stock for the aggregate gross proceeds of $18,160,000 on March 13, 2024. Each share of Series B Preferred Stock is convertible at the option of the holder, from and after the six-month anniversary of its issuance, subject to the beneficial ownership and primary market limitations into such number of shares of the Company?s common stock, par value $0.001 per share as is equal to the number of shares of Series B Preferred Stock to be converted, multiplied by the stated value of $1,000 divided by the conversion price in effect at the time of the conversion. The initial conversion price will be $1.2444, subject to adjustment in the event of stock splits, stock dividends, and similar transactions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9444 USD | +1.58% | +1.58% | -33.02% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.02% | 47.02M | |
+73.46% | 12.41B | |
-15.61% | 8.23B | |
+3.88% | 6.46B | |
+14.69% | 5.5B | |
+42.58% | 5.1B | |
-19.05% | 4.05B | |
-32.61% | 2.54B | |
-0.74% | 1.99B | |
+10.80% | 1.99B |
- Stock Market
- Equities
- LUCD Stock
- News Lucid Diagnostics Inc.
- Lucid Diagnostics Inc. announced that it has received $18.16 million in funding